Merck Manual

Please confirm that you are a health care professional

honeypot link

Burkitt Lymphoma


Peter Martin

, MD, Weill Cornell Medicine;

John P. Leonard

, MD, Weill Cornell Medicine

Reviewed/Revised May 2022 | Modified Sep 2022
Topic Resources

Burkitt lymphoma is an aggressive B-cell non-Hodgkin lymphoma occurring in children and adults. Endemic (African), sporadic (non-African), and immunodeficiency-related forms exist.

Classic Burkitt lymphoma is endemic in central Africa and constitutes 30% of childhood lymphomas in the US. The form endemic to Africa often manifests as enlargement of the jaw or facial bones.

In sporadic (non-African) Burkitt lymphoma, abdominal disease predominates, often arising in the region of the ileocecal valve or the mesentery. Tumor may cause bowel obstruction. Extranodal sites such as the brain or other solid organs may also be involved. In adults, disease may be bulky and generalized, often with massive involvement of liver, spleen, and bone marrow. Central nervous system (CNS) involvement is often present at diagnosis or with relapsing lymphoma.

Burkitt lymphoma is the most rapidly growing human tumor, and pathology reveals a high mitotic rate, a monoclonal proliferation of B cells, and a “starry-sky” pattern of benign macrophages that have engulfed apoptotic malignant lymphocytes. On FDG-PET (fluorodeoxyglucose-positron emission tomography) scans, the tumors are highly metabolic. There is a distinctive genetic translocation involving the C-myc gene on chromosome 8 and the immunoglobulin heavy chain of chromosome 14. The disease is closely associated with Epstein-Barr virus infection Infectious Mononucleosis Infectious mononucleosis is caused by Epstein-Barr virus (EBV, human herpesvirus type 4) and is characterized by fatigue, fever, pharyngitis, and lymphadenopathy. Fatigue may persist weeks or... read more Infectious Mononucleosis in endemic lymphoma; however, it is uncertain whether Epstein-Barr virus plays an etiologic role. Burkitt lymphoma occurs frequently in patients with HIV/AIDS and is an AIDS-defining disease .

Diagnosis of Burkitt Lymphoma

  • Lymph node or bone marrow biopsy

  • Rarely, laparoscopy

Histopathologic diagnosis is based on biopsy of lymph node or tissue from another suspected disease site, such as the bone marrow. Rarely, laparoscopy may be used for both diagnosis and treatment.

Staging studies must be expedited because the tumor grows rapidly. Staging includes fluorodeoxyglucose (FDG)-positron emission tomography (PET)/CT tumor imaging; if unavailable, CT of the chest, abdomen, and pelvis may be done instead. Patients should also have bone marrow biopsy, cerebrospinal fluid cytology, and laboratory studies to include lactate dehydrogenase (LDH).

Treatment of Burkitt Lymphoma

  • Intensive chemotherapy

Treatment must be initiated rapidly because these tumors grow rapidly. An intensive alternating regimen of cyclophosphamide, vincristine, doxorubicin, methotrexate, ifosfamide, etoposide, and cytarabine (CODOX-M/IVAC) plus rituximab results in a cure rate of > 80% for children and adults < 60 years. For patients > 60 years, regimens such as rituximab plus etoposide, prednisone, vincristine (Oncovin), and doxorubicin (dose-adjusted R-EPOCH) are also commonly used with success. For patients without CNS metastases, CNS prophylaxis (eg, with systemic and/or intrathecal methotrexate and/or cytarabine) is essential.

If the patient presents with bowel obstruction secondary to tumor but the tumor is completely resected at initial diagnostic-therapeutic laparotomy, then aggressive therapy is still indicated, but fewer cycles may be needed. Patients at the end of treatment should have a complete metabolic response documented by PET or a complete response documented by CT scan and bone marrow biopsy. Outcome is poor in the 20% of patients in whom induction fails or relapse (typically in the first 12 months) occurs. Salvage therapy or clinical trials should be considered.

More Information

The following is an English language resource that provides information for clinicians and support and information for patients. THE MANUAL is not responsible for the content of this resource.

Drugs Mentioned In This Article

Drug Name Select Trade
Cyclophosphamide, Cytoxan, Neosar
Oncovin, Vincasar PFS
Adriamycin, Adriamycin PFS, Adriamycin RDF, Rubex
Jylamvo, Otrexup, Rasuvo, RediTrex, Rheumatrex, Trexall, Xatmep
Etopophos, Toposar, VePesid
RIABNI, Rituxan, RUXIENCE, truxima
Deltasone, Predone, RAYOS, Sterapred, Sterapred DS
Aloprim, Zyloprim
NOTE: This is the Professional Version. CONSUMERS: View Consumer Version
quiz link

Test your knowledge

Take a Quiz!